高级检索
当前位置: 首页 > 详情页

Role of the Wnt/β-catenin signaling pathway in inducing apoptosis and renal fibrosis in 5/6-nephrectomized rats.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Nephrology, People's Hospital of Guizhou Province, Guiyang, Guizhou 550002 [2]Department of Nephrology, Loudi Central Hospital, Loudi, Hunan 417000 [3]Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital,Guangzhou University of Traditional Chinese Medicine, Shenzhen, Guangdong 518033 [4]Department of Nephrology, Ruikang Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi 530011, P.R. China
出处:
ISSN:

关键词: chronic kidney disease Wnt/β‑catenin signaling apoptosis fibrosis renal

摘要:
Renal fibrosis is the final common pathway of all progressive renal disease. Excessive and chronic activation of the Wnt/β-catenin signaling pathway results in chronic kidney disease (CKD) progression. To mimic CKD, the present study used 5/6-nephrectomized rats, and alterations in kidney histology, expression of β‑catenin and renal cell apoptosis were assessed. In addition, mesangial cells were cultured in vitro and transfected with β‑catenin siRNA to evaluate the effect of blocking Wnt/β‑catenin signaling on cell apoptosis and the expression of markers of renal fibrosis. The results demonstrated that CKD rat kidney tissues exhibited moderate renal fibrosis and significantly increased expression levels of β‑catenin and apoptosis associated proteins compared with sham‑operated rats. In vitro, silencing of β-catenin by siRNA attenuated tumor necrosis factor‑α‑induced apoptosis and decreased mRNA expression levels of various markers of fibrosis, including fibronectin, transforming growth factor‑β, and collagen I, III and IV. In conclusion, inhibition of Wnt/β‑catenin signaling by β‑catenin silencing attenuated apoptosis and expression of fibrosis-associated markers in renal cells. The present study suggested that the Wnt/β‑catenin signaling pathway may serve as a potential treatment strategy for renal fibrotic disorders.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
JCR分区:
出版当年[2015]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 ONCOLOGY
最新[2023]版:
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Department of Nephrology, People's Hospital of Guizhou Province, Guiyang, Guizhou 550002
共同第一作者:
通讯机构: [*1]Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Traditional Chinese Medicine, 1 Fuhua Road, Shenzhen, Guangdong 518033, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号